To include your compound in the COVID-19 Resource Center, submit it here.

Takeda's TAK-875 meets diabetes endpoint

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) said all doses of once-daily

Read the full 102 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE